What is the recommended antibiotic regimen for treating suspected or confirmed Clostridioides difficile colitis in adults, including first‑line therapy, severity‑adjusted dosing, and special considerations?

Antibiotic Treatment for Clostridioides difficile Colitis

For initial episodes of C. difficile infection, use oral vancomycin 125 mg four times daily for 10 days regardless of severity, as this is now strongly preferred over metronidazole based on the 2018 IDSA/SHEA guidelines. 1

First-Line Therapy for Initial Episodes

Non-Severe CDI

• Oral vancomycin 125 mg four times daily for 10 days is the preferred first-line agent (strong recommendation, high quality evidence) 1, 2
• Alternatively, fidaxomicin 200 mg twice daily for 10 days can be used and may reduce recurrence rates (strong recommendation, moderate quality evidence) 1, 3
• Metronidazole is no longer recommended as first-line therapy, though it may be considered if vancomycin and fidaxomicin are unavailable 1
• Non-severe disease is defined as WBC ≤15,000 cells/mL and serum creatinine <1.5 mg/dL 2

Severe CDI

• Oral vancomycin 125 mg four times daily for 10 days remains the standard dose even for severe disease (strong recommendation, high quality evidence) 1, 2
• Severe disease is defined as WBC ≥15,000 cells/mL or serum creatinine >1.5 mg/dL 2
• The 2018 IDSA/SHEA guidelines emphasize that vancomycin is superior to metronidazole in severe cases 1

Fulminant CDI

For fulminant CDI (hypotension/shock, ileus, or megacolon), escalate to high-dose oral vancomycin 500 mg four times daily PLUS intravenous metronidazole 500 mg every 8 hours (strong recommendation, moderate quality evidence) 1, 4, 2

• If ileus is present or oral intake is compromised, add rectal vancomycin 500 mg in 100 mL normal saline every 6 hours as a retention enema (weak recommendation, low quality evidence) 1, 4
• This triple therapy (high-dose oral vancomycin + IV metronidazole + rectal vancomycin) represents maximal medical management 4
• IV metronidazole is critical because it achieves therapeutic concentrations in inflamed colonic tissue when oral delivery may be impaired by ileus 1, 4

Severity-Adjusted Dosing Algorithm

Step 1: Assess Disease Severity

• Check WBC count, serum creatinine, and clinical signs (hypotension, ileus, megacolon) 1, 2

Step 2: Select Initial Regimen

• Non-severe: Vancomycin 125 mg PO QID × 10 days 1
• Severe: Vancomycin 125 mg PO QID × 10 days 1
• Fulminant: Vancomycin 500 mg PO QID + metronidazole 500 mg IV Q8H × 10 days 1, 4
• Fulminant with ileus: Add vancomycin 500 mg PR Q6H 1, 4

Step 3: Consider Treatment Duration

• Standard duration is 10 days, but may extend to 14 days if clinical response is delayed 1, 4

Treatment of Recurrent CDI

First Recurrence

Use a prolonged tapered and pulsed vancomycin regimen rather than repeating a standard 10-day course (weak recommendation, low quality evidence) 1

• Tapered and pulsed regimen: Vancomycin 125 mg four times daily for 10-14 days, then twice daily for 7 days, then once daily for 7 days, then every 2-3 days for 2-8 weeks 1
• Alternative: Fidaxomicin 200 mg twice daily for 10 days (weak recommendation, moderate quality evidence) 1
• If metronidazole was used for the initial episode, use standard vancomycin 125 mg four times daily for 10 days rather than repeating metronidazole 1

Second or Subsequent Recurrences

• Vancomycin tapered and pulsed regimen as described above (weak recommendation, low quality evidence) 1
• Vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days (weak recommendation, low quality evidence) 1
• Fidaxomicin 200 mg twice daily for 10 days (weak recommendation, low quality evidence) 1
• Fecal microbiota transplantation (FMT) is strongly recommended for patients with multiple recurrences who have failed appropriate antibiotic treatments (strong recommendation, moderate quality evidence) 1

Special Considerations and Critical Management Principles

Discontinue Inciting Antibiotics

• Immediately discontinue the causative antibiotic if possible, as continued antibiotic use significantly increases recurrence risk (strong recommendation, moderate quality evidence) 1, 4, 2
• If continued antibiotic therapy is required for another infection, use agents less frequently associated with CDI: parenteral aminoglycosides, sulfonamides, macrolides, vancomycin, or tetracycline/tigecycline 1

Avoid Antiperistaltic Agents

• Never use antiperistaltic agents or opiates as they worsen outcomes and increase complications 2

Infection Control Measures

• Use contact precautions and hand hygiene with soap and water (not alcohol-based sanitizers, which don't kill C. difficile spores) 1
• Alcohol-based hand sanitizers are ineffective against C. difficile spores; handwashing with soap and water is essential 1

Monitoring for Systemic Absorption

• Monitor serum vancomycin trough concentrations in patients with renal failure, disrupted intestinal integrity, or inflammatory bowel disease, as systemic absorption can occur with high doses 1, 5
• Clinically significant serum concentrations have been reported in patients with active CDI and inflammatory disorders of the intestinal mucosa 5

Proton Pump Inhibitors

• While PPIs are associated with CDI, there is insufficient evidence to mandate discontinuation in all cases 1
• However, stewardship activities to discontinue unneeded PPIs are warranted 1

Surgical Considerations

Indications for Early Surgical Consultation

Obtain early surgical consultation for patients with fulminant CDI who show clinical deterioration despite maximal medical therapy 4

• Rising WBC count (≥25,000) or rising lactate level (≥5 mmol/L) is associated with high mortality and indicates need for early surgery 1, 4
• Worsening imaging findings (colonic wall thickening, pericolonic fat stranding, ascites, early megacolon) despite 48-72 hours of maximal medical therapy warrant urgent surgical evaluation 4
• Clinical deterioration including hypotension/shock, end-organ dysfunction, or worsening leukocytosis despite therapy necessitates immediate surgical consultation 4

Surgical Options

• Subtotal colectomy with end ileostomy is the traditional approach with proven survival benefit 1, 4
• Diverting loop ileostomy with intraoperative colonic lavage followed by antegrade vancomycin flushes is a colon-sparing alternative that may improve outcomes (weak recommendation, low quality evidence) 1, 4
• Surgery should be considered within 48-96 hours of starting maximal medical therapy if no clinical improvement occurs 4

Pediatric Dosing (6 Months to <18 Years)

Non-Severe CDI

• Vancomycin 10 mg/kg/dose (maximum 125 mg) four times daily for 10 days (weak recommendation, low quality evidence) 1, 2
• Alternatively, metronidazole 7.5 mg/kg/dose (maximum 500 mg) three or four times daily for 10 days 1

Severe/Fulminant CDI

• Vancomycin 10 mg/kg/dose (maximum 500 mg) four times daily for 10 days (strong recommendation, moderate quality evidence) 1, 2
• Consider adding IV metronidazole 10 mg/kg/dose (maximum 500 mg) three times daily in severe or fulminant cases (weak recommendation, low quality evidence) 1

Recurrent CDI in Children

• For second or subsequent recurrences, use vancomycin tapered and pulsed regimen or consider FMT (weak recommendation, low quality evidence) 1

Common Pitfalls to Avoid

• Do not use parenteral (IV) vancomycin for CDI treatment—it is completely ineffective as it is not excreted into the colon 2, 5
• Do not use metronidazole as first-line therapy for initial episodes, as the 2018 guidelines now strongly prefer vancomycin or fidaxomicin 1
• Do not delay surgical consultation in fulminant cases—early intervention improves outcomes 1, 4
• Do not treat asymptomatic carriers—treatment is only indicated for symptomatic patients 1
• Do not use higher vancomycin doses (500 mg) for non-fulminant disease—the standard 125 mg dose is equally effective and more cost-effective 1

Adjunctive Therapies

Bezlotoxumab

• Bezlotoxumab (monoclonal antibody against toxin B) may prevent recurrences, particularly in high-risk patients (027 epidemic strain, immunocompromised, severe CDI) 1
• Administered as a single IV infusion during antibiotic treatment 1

Fecal Microbiota Transplantation

• FMT is highly effective for multiple recurrences (≥3 episodes) after appropriate antibiotic treatments have failed (strong recommendation, moderate quality evidence) 1
• FMT restores normal colonic flora disrupted by C. difficile overgrowth 1